CMMB vs AWRE Comparison

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Aware Inc provides biometric identity and authentication solutions. Its Awareness Platform transforms biometric data into actionable intelligence, allowing its clients to verify identities and authenticate access and transactions. The company's products span multiple biometric modalities, including fingerprint, face, iris, and voice. It offers: a broad range of biometrics software products and solutions, including platforms like AwareSDK, AwareABIS, AFIX Suite of Products, Awareness Platform, and WebEnroll; software components such as SDKs, APIs, and applications that customers use to develop their systems into more effective solutions; and several program management and software engineering services. Aware earns maximum revenue from the U.S., followed by the UK and the rest of the world.